Related Experiment Video

Updated: Jun 14, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Anti-tumour necrosis factor-alpha treatment for perianal Crohn's disease in Australia

Daniel C Burger1, Ian C Lawrance, Peter A Bampton

  • 1Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.

The Medical Journal of Australia
|April 7, 2010
PubMed

Insights

Many patients with perianal Crohn's disease (PCD) cannot access anti-tumour necrosis factor-alpha (anti-TNFalpha) treatments due to current Australian Pharmaceutical Benefits Scheme (PBS) guidelines. This study highlights the need to expand PBS criteria for this patient group.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacoeconomics

Background:

  • Perianal Crohn's disease (PCD) affects a significant portion of inflammatory bowel disease (IBD) patients.
  • Access to advanced therapies like anti-tumour necrosis factor-alpha (anti-TNFalpha) is crucial for managing severe PCD.
  • Current Australian Pharmaceutical Benefits Scheme (PBS) guidelines may limit access to these essential treatments.

Purpose of the Study:

  • To determine the prevalence of PCD within a large Australian IBD cohort.
  • To assess the eligibility of PCD patients for PBS-subsidised anti-TNFalpha therapy.
  • To identify gaps in current PBS criteria for optimal PCD management.

Main Methods:

  • Retrospective analysis of 3589 IBD patients from four Australian centres (2004-2008).
  • Identification of patients with Crohn's disease (CD) and specifically PCD.
  • Evaluation of anti-TNFalpha therapy indication and PBS eligibility for PCD patients.

Main Results:

  • Out of 1815 CD patients, 310 (17%) had PCD.
  • Anti-TNFalpha therapy was indicated for 166 (54%) PCD patients.
  • 49 (30%) of indicated PCD patients did not meet PBS criteria for subsidised treatment.

Conclusions:

  • A substantial proportion of patients with clinically significant PCD are denied optimal medical treatment.
  • Current PBS criteria for anti-TNFalpha therapy require revision to include this vulnerable IBD subgroup.
  • Expanding PBS access could improve outcomes for Australian patients with perianal Crohn's disease.
Abstract

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...